Isatuximab

Lymphoma

Divaya Bhutanimonoclonal_antibodyPhase 2Active

B

56/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 51/ 100
Competitive Position: 65/ 100

Competitive context

287 Active assets in the Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Vinblastine Intensity Therapeutics, Inc.	Phase 4	BBB
Prednisolone The Lymphoma Academic Research Organisation	Phase 4	BBB
Cyclophosphamide Beth Israel Deaconess Medical Center	Phase 4	BB
Vincristine Sulfate Inhye Ahn	Phase 3	BB
Bleomycin Shandong Provincial Hospital	Phase 4	BB

View all 50 →

Same molecule, other indications

Isatuximab is also rated in:

plasma cell myelomaActive

BB

Indicative · Phase 4

68 / 100

non-Hodgkin lymphomaActive

B

Indicative · Phase 2

60 / 100

extranodal nasal NK/T cell lymphomaDormant

B

Indicative · Phase 2

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.